Re: At least RVX has a shorter trial timeline than ESPR
in response to
by
posted on
May 05, 2016 05:18PM
Just following up on my last rambling post.
What I was trying so say at the end of my last post is that perhaps the multiple pathway effects (Pathways affected include complement cascade, acute phase response, coagulation/fibrin clotting cascade, inflammation and calcification.) caused by apabetalone are so remarkable that scientists, investors and BP do not believe it?
Perhaps this is where doubt resides? But this information has been proven.
Had to get that out of my head.
Cheers
Toinv